HCV multi-epitope peptide, truncated NS3, and DC activating molecule EDA recombinant protein vaccine and applications thereof

Abstract

The invention discloses a HCV multi-epitope peptide, truncated NS3, and DC activating molecule EDA recombinant protein vaccine and applications thereof. The recombinant protein vaccine comprises the following components: EDA, deltaNS3 and three HCV multi-epitopes, whose nucleic acid sequence is represented by the SEQ. ID. No.1. The HCVEDA-deltaNS3-VAL-44 protein can induce a specific humoral immune response and T cell immune response, the T cell can rapidly generate IFN-gamma and generate high efficient CTL after being stimulated by a specific antigen, and the HCV multi-epitope peptide, truncated NS3, and DC activating molecule EDA recombinant protein vaccine is probably an ideal HCV preventive / therapeutic candidate vaccine.

Description

technical field [0001] The invention belongs to the technical field of HCV vaccines, and relates to a recombinant protein vaccine of HCV multi-epitope peptide, truncated NS3 and DC activating molecule EDA and application thereof. Background technique [0002] Hepatitis C virus (hepatitis C virus, HCV), a single-stranded positive-sense hepatotropic RNA virus of the flavivirus genus, is the main pathogen that causes chronic liver disease. There are about 170 million infected people in the world, and the number of cases is 3 million per year. increment. Chronic HCV infection is directly related to liver cirrhosis and liver cancer, seriously affecting the quality of life of patients. Due to the high cost and unsatisfactory efficacy of standard HCV treatment regimens, most HCV-infected patients in developing countries cannot afford it. Therefore, the development of HCV vaccine has become one of the most effective strategies to reduce the incidence of liver cirrhosis and liver c...

AI Technical Summary

Problems solved by technology

[0008] The arrangement and combination of SAAL (VAL-44 for short) has the best effect. After subcutaneously immunizing HHD-2 mice with this HCV polypeptide vaccine, it can cause splenocyte proliferation, increase the percentage of CD4+ and CD8+ T lymphocytes, and increase the percentage of Th1 type T lymphocytes. Response-based cellular immune response, but generally speaking, the immune effect is not very satisfactory. In order to overcome the defect of weak immunogenicity of peptide vaccines, we finally chose Fibronectin Extra Domain A (EDA ), combined with truncated NS3 inserted into the upstream of the three multi-epitopes, to construct the EDA-ΔNS3-VAL-44 prokaryotic expression vector, after inducing protein expression, and purifying the EDA-ΔNS3-VAL-44 target protein, supplemented with The immune adjuvant poly(I:C) (Yu-sheng Cheng and Feng Xu. Anticancer function of polyinosinic-polycytidylic acid. Cancer Biology & Therapy.2010;10:1219-1223) that activates Toll-like receptor 3 was administered to mice immunity

Images